Home / Resource Library / Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

Results of a phase II study examining zanubrutinib for treatment of relapsed DLBCL.